ALCLS Stock Overview
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cellectis S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.41 |
| 52 Week High | €3.44 |
| 52 Week Low | €0.89 |
| Beta | 3.13 |
| 1 Month Change | 1.05% |
| 3 Month Change | -4.18% |
| 1 Year Change | 35.88% |
| 3 Year Change | -85.02% |
| 5 Year Change | -86.49% |
| Change since IPO | -83.71% |
Recent News & Updates
Recent updates
A Look At The Intrinsic Value Of Cellectis S.A. (EPA:ALCLS)
Feb 07
Analyst Forecasts Just Became More Bearish On Cellectis S.A. (EPA:ALCLS)
Aug 09Is Cellectis (EPA:ALCLS) Using Too Much Debt?
Dec 14Analysts' Revenue Estimates For Cellectis S.A. (EPA:ALCLS) Are Surging Higher
Aug 07We Think Some Shareholders May Hesitate To Increase Cellectis S.A.'s (EPA:ALCLS) CEO Compensation
May 26Is Cellectis (EPA:ALCLS) Using Debt Sensibly?
May 17These Analysts Think Cellectis S.A.'s (EPA:ALCLS) Sales Are Under Threat
Mar 08Cellectis (EPA:ALCLS) Is In A Strong Position To Grow Its Business
Feb 16Are Institutions Heavily Invested In Cellectis S.A.'s (EPA:ALCLS) Shares?
Jan 12
Analysts Are Betting On Cellectis S.A. (EPA:ALCLS) With A Big Upgrade This Week
Dec 08Shareholder Returns
| ALCLS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | 2.6% | 3.1% | 2.2% |
| 1Y | 35.9% | -9.1% | 3.2% |
Return vs Industry: ALCLS exceeded the French Biotechs industry which returned -9.1% over the past year.
Return vs Market: ALCLS exceeded the French Market which returned 3.2% over the past year.
Price Volatility
| ALCLS volatility | |
|---|---|
| ALCLS Average Weekly Movement | 6.7% |
| Biotechs Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.6% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALCLS has not had significant price volatility in the past 3 months.
Volatility Over Time: ALCLS's weekly volatility has decreased from 28% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 234 | Andre Choulika | www.cellectis.com |
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma. It also develops UCART22 to treat B-cell acute lymphoblastic leukemia; UCARTCS1 and ALLO-605 for the treatment of multiple myeloma; ALLO-316 for renal cell carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART 20x22 for relapsed or refractory B-Cell NHL.
Cellectis S.A. Fundamentals Summary
| ALCLS fundamental statistics | |
|---|---|
| Market cap | €172.56m |
| Earnings (TTM) | -€67.17m |
| Revenue (TTM) | €22.92m |
7.5x
P/S Ratio-2.6x
P/E RatioIs ALCLS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALCLS income statement (TTM) | |
|---|---|
| Revenue | US$24.53m |
| Cost of Revenue | US$1.26m |
| Gross Profit | US$23.26m |
| Other Expenses | US$95.15m |
| Earnings | -US$71.89m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 94.86% |
| Net Profit Margin | -293.13% |
| Debt/Equity Ratio | 41.4% |
How did ALCLS perform over the long term?
See historical performance and comparison